Onco360 Adds 4 Pfizer LDD Products
Each of the new additions to Onco360’s portfolio have been approved by the U.S. Food and Drug Administration (FDA) as targeted therapies in comprehensive cancer treatment:
- Bosulif, a treatment for chronic, accelerated, or blast phase Philadelphia chromosome positive chronic myelogenous leukemia in adult patients with resistance or intolerance to prior therapy;
- Inlyta, a treatment for advanced renal cell carcinoma in patients after failure of one prior systemic therapy;
- Sutent, a treatment for three forms of cancer, including advanced renal cell carcinoma, gastrointestinal stromal tumors, and pancreatic neuroendocrine tumors; and
- Xalkori, a treatment for patients with metastatic ALK-positive non-small cell lung cancer.
“We are pleased to expand our relationship with Pfizer, and we look forward to collaborating on our shared goal of advancing innovative solutions to shape the future of cancer care,” said Paul Jardina, President and CEO of Onco360. “Our relationships with the leaders in pharmaceutical manufacturing, including Pfizer, are a critical component of Onco360’s mission to be the country’s most comprehensive source for oncology pharmacy and clinical support services.”
“Cancer care is complex and dynamic, and it requires a unique focus and dedication from a pharmacy practice standpoint,” said Burt Zweigenhaft, Vice Chairman and Chief Strategy Officer of Onco360. “At Onco360, we pride ourselves on providing our patients with robust treatment options, and the addition of these four drugs to our offering advances our mission of providing the highest level of support for cancer patients and the healthcare teams dedicated to their care.”
All four products are immediately available for order through Onco360. Information on how to order can be obtained by visiting www.Onco360.com/How To Order.